Itepekimab (SAR440340) + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Bronchiectasis

Conditions

Bronchiectasis

Trial Timeline

Feb 20, 2024 → Feb 2, 2026

NCT ID

NCT06280391

About Itepekimab (SAR440340) + Placebo

Itepekimab (SAR440340) + Placebo is a phase 2 stage product being developed by Sanofi for Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT06280391. Target conditions include Bronchiectasis.

What happened to similar drugs?

1 of 10 similar drugs in Bronchiectasis were approved

Approved (1) Terminated (2) Active (8)

✅Aztreonam lysineGilead SciencesApproved

❌Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3

🔄Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3

🔄Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3

🔄AZLI + PlaceboGilead SciencesPhase 3

🔄HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07484230	Phase 3	Recruiting	May 8, 2026	Oct 10, 2028	Chronic Rhinosinusitis With Nasal Polyps
NCT07424144	Phase 3	Recruiting	Mar 12, 2026	Dec 12, 2028	Chronic Rhinosinusitis With Nasal Polyps
NCT06280391	Phase 2	Completed	Feb 20, 2024	Feb 2, 2026	Bronchiectasis
NCT06208306	Phase 3	Active	Jan 11, 2024	Dec 1, 2026	Chronic Obstructive Pulmonary Disease

Competing Products

20 competing products in Bronchiectasis

See all competitors

Product	Company	Stage	Hype Score
Benralizumab + Placebo to Benralizumab	AstraZeneca	Phase 3	32
AZD9668 + Placebo	AstraZeneca	Phase 2	35
AZD5069 + Placebo	AstraZeneca	Phase 2	35
AZD0292	AstraZeneca	Phase 2	42
TIP + TIP and placebo + Placebo	Novartis	Phase 2	35
Ciprofloxacin DPI (BAYQ3939) + Placebo	Novartis	Phase 3	40
Placebo to Ciprofloxacin DPI (BAYQ3939)	Novartis	Pre-clinical	26
Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + Placebo	Novartis	Phase 3	40
QBW251 + Placebo	Novartis	Phase 2	27
Ciprofloxacin (Cipro, BAYQ3939) + Placebo	Novartis	Phase 2	35
AZLI + Placebo	Gilead Sciences	Phase 3	40
Aztreonam lysine	Gilead Sciences	Approved	35
AZLI	Gilead Sciences	Phase 2	35
AZLI + Placebo	Gilead Sciences	Phase 3	40
CSL787 + Placebo	CSL	Phase 1	29
CSL787 + Placebo	CSL	Phase 2	42
HSK31858, tablet + Placebo	Haisco Pharmaceutical Group	Phase 3	47
HSK31858 + placebo	Haisco Pharmaceutical Group	Phase 2	35
Group A + Group B	Bayer	Pre-clinical	23
BAY85-8501 + Placebo	Bayer	Phase 2	32